01136nas a2200373   4500000000100000000000100001000000100002008004100003653003100044653004400075653005600119653002600175653003100201653003200232653001100264653001600275653003700291653004400328653002300372653002700395653001400422653002800436653003200464653002700496653002400523100001400547700002000561700001300581245012000594250001500714300001200729490000700741020001400748       2022                            d10aAdministration, Inhalation10aAdrenal Cortex Hormones/therapeutic use10aAdrenergic beta-2 Receptor Agonists/therapeutic use10aBronchodilator Agents10aBudesonide/adverse effects10aFluticasone/therapeutic use10aHumans10aMiddle Aged10a*Pneumonia/epidemiology/etiology10a*Pulmonary Disease, Chronic Obstructive10aCOPD exacerbations10aNew-user cohort design10apneumonia10ainhaled corticosteroids10along-acting bronchodilators10aobservational research10areal-world evidence1 aS. Suissa1 aS. Dell'Aniello1 aP. Ernst00aFluticasone-Based versus Budesonide-Based Triple Therapies in COPD: Real-World Comparative Effectiveness and Safety  a2022/04/07  a109-1170 v19  a1541-2563